Competitive & Portfolio Intelligence guide
AI for pharma competitive intelligence: landscapes, conferences, KOLs and probability of success
How AI tools for pharma competitive intelligence handle trial landscapes, conference abstracts, KOL discovery and probability of success, with a buyer checklist.
AI tools for pharma competitive intelligence do four jobs: build trial landscapes, analyze conference abstracts, find key opinion leaders (KOLs), and estimate probability of success. The established options are curated databases with AI assistants (Citeline Trialtrove+, Clarivate Cortellis, GlobalData), forecast platforms (Evaluate), AI search over market content (AlphaSense), and AI agents that work from primary sources (TrialMind from Keiji AI). Judge any of them on coverage, freshness, and whether every claim links to its source.
What AI changes in competitive intelligence
Competitive intelligence in drug development means tracking what rivals are testing, where, and how it is going. The raw material is public: trial registries, publications, conference abstracts, filings and press releases.
The hard part is volume and speed. A single large oncology meeting can produce thousands of abstracts. A target like KRAS G12C has well over a hundred active trials.
AI helps in three places:
- Reading. Extracting drug, sponsor, phase, population and endpoints from free text.
- Organizing. Normalizing drug names, grouping by mechanism, setting and sponsor, and removing duplicates.
- Answering. Turning a plain-language question into a search, then a sourced answer.
AI does not remove the need for judgment. An analyst still decides which trials compete, what counts as a meaningful result, and what to tell the committee.
Trial landscapes
A trial landscape lists every relevant trial by drug, sponsor, phase, setting and status. Tools take two approaches.
- Curated databases. Analysts maintain a dataset ahead of time. Citeline Trialtrove+ lists 555,000+ trials from 70,000+ sources, manually curated. GlobalData draws on 250+ trial registries plus conferences, pipelines, press releases and SEC filings. Cortellis combines curated pipeline, clinical, regulatory, deal and patent data.
- Agents over primary sources. The tool reads registries and papers when you ask. TrialMind reads ClinicalTrials.gov, EudraCT, other registries, publications and conference abstracts directly, and links each claim to its source.
The research behind this approach is published. Keiji AI's TrialPanorama (npj Digital Medicine, 2025) is a database of 1,060K+ trials from 15 sources used to benchmark and train language models. Panacea (medRxiv preprint, 2024) is a foundation model for clinical trial search, summarization, design and recruitment.
Curated databases give consistency and history. Agents give custom scope and a direct link to the record. For a worked example of the manual method, see our KRAS G12C trial landscape guide.
Conference abstract analysis
New data often appears first as a conference abstract. Competitive intelligence teams need to read a meeting's abstracts quickly and find what competitors presented.
Keiji AI's AACR 2026 abstract analysis is one example. It covered all 6,769 abstracts from the American Association for Cancer Research Annual Meeting (April 17–22, 2026, San Diego). It grouped them into 7 research categories and 50 topic areas, with 10.3 topics per abstract on average.
The most common topics included immunotherapy combinations, the tumor microenvironment, liquid biopsy and ctDNA, antibody-drug conjugates and CAR-T cell therapy.
When you evaluate a tool for conference work, ask:
- Which meetings does it cover, and how soon after release are abstracts available?
- Can it group abstracts by author organization, so you see what each competitor presented?
- Does each finding link back to the abstract?
Among the curated databases, Trialtrove+ lists medical meetings among its sources, Cortellis says its intel is sourced from global conferences and news, and GlobalData lists scientific and investor conferences.
Key opinion leader discovery
KOL discovery means finding the investigators who lead work on a mechanism or indication. Good signals are public: principal investigators on trials, authors of recent papers, and presenters at meetings.
TrialMind identifies KOLs from trials, publications and abstracts, each linked to its source. The same abstract collection used for conference analysis supports KOL discovery.
Check how a tool resolves author names. The same person often appears with different initials and affiliations. Without name resolution, one investigator becomes three.
Probability of success
Probability of success (PoS) estimates how likely a program is to advance to the next phase or reach approval. Portfolio committees use it to weigh funding decisions.
What the published evidence says
Baseline rates vary by source and method. Wong, Siah and Lo (Biostatistics, 2019) used 406,038 trial data entries for over 21,143 compounds from 2000 to 2015. They found oncology had a 3.4% success rate in their sample, against 5.1% in prior studies. They also found that trials using biomarkers for patient selection had higher overall success than trials without them.
Machine learning models predict outcomes for individual trials. HINT (Patterns, 2022), co-authored by Keiji AI's Jimeng Sun, encodes the drug molecule, target disease and eligibility criteria. It was trained on 1,160 phase I, 4,449 phase II and 3,436 phase III trials, with F1 scores of 0.665, 0.620 and 0.847 on separate test sets.
What vendors offer
- Cortellis Drug Timeline & Success Rates: a machine learning algorithm on 22+ years of curated data, forecasting launch dates and phase-by-phase success.
- GlobalData Likelihood of Approval: phase transition success rates from 108 Random Forest models across 18 therapy areas, compounded into a probability of US approval.
- Evaluate Product Specific PTRS: a product-level probability of technical and regulatory success from 50+ drug, company and market attributes (launched 2019).
- TrialMind: estimated technical and regulatory success by phase, with risk factors and a method described in peer-reviewed papers.
Accuracy figures on vendor pages are the vendors' own. Ask how a model was validated, on which trials, and whether you can see which factors moved the estimate.
Source traceability
A competitive read is only useful if someone can check it. When a number reaches a portfolio review, the first question is often "where did that come from?"
Ask every vendor:
- Does each statement link to the trial record, publication or abstract behind it?
- When the AI summarizes, can you see the passage it summarized?
- Is the method for scores such as PoS documented?
Several products describe citable answers. AlphaSense says Generative Search returns "citable, verifiable answers". Evaluate describes Ask Ella as built for citable answers. TrialMind links every claim to the record, publication or abstract it came from.
Types of tools, and when each fits
| Type | Examples | Fits when |
|---|---|---|
| Curated trial and pipeline databases | Citeline Trialtrove+, Cortellis, GlobalData | You want a maintained dataset with history, benchmarks and analyst support. |
| Forecast-led platforms | Evaluate Pharma | Commercial questions lead: consensus sales forecasts tied to pipelines. |
| AI search over market content | AlphaSense | You need broker research, expert calls, filings and news alongside clinical sources. |
| AI agents over primary sources | TrialMind | You need custom analyses from registries, publications and abstracts, with every claim sourced. |
Many teams combine types. For a side-by-side table, see TrialMind, Trialtrove+, Cortellis and other trial intelligence tools compared.
Buyer checklist
- Coverage. Which registries (ClinicalTrials.gov, CTIS, EU Clinical Trials Register, national registries), which meetings, which publication databases?
- Freshness. How soon do new trials and abstracts appear?
- Normalization. Does it map drug code names to generic names and remove duplicate registrations?
- Traceability. Does every claim link to its source record?
- Custom questions. Can you ask your own question, or only filter a fixed dataset?
- PoS method. Is the probability-of-success model documented and validated? Can you see the drivers?
- Delivery. Platform, data feed, API or MCP? Does it fit your team's tools?
- Start-up effort. Does it need a validation project? Work with no patient data usually does not.
- A test. Give every shortlisted vendor the same question, such as a KRAS G12C landscape, and check the answers against the registry.
Frequently asked questions
- What are the best AI tools for pharma competitive intelligence?
- Commonly used options are Citeline Trialtrove+, Clarivate Cortellis, GlobalData, Evaluate Pharma and AlphaSense. TrialMind from Keiji AI uses AI agents over registries, publications and conference abstracts with a source link for every claim. The best fit depends on whether you need a curated dataset, forecasts, market research or custom sourced analyses.
- Which tools analyze conference abstracts like ASCO or AACR?
- Trialtrove+, Cortellis and GlobalData list medical meetings or conferences among their sources. TrialMind processes abstracts from major meetings as they are presented; Keiji AI's AACR 2026 analysis covered all 6,769 abstracts.
- What tools predict probability of success for clinical trials?
- Cortellis (Drug Timeline & Success Rates), GlobalData (Likelihood of Approval) and Evaluate (Product Specific PTRS) offer commercial models. TrialMind estimates success by phase with risk factors. Published research such as HINT and Wong, Siah and Lo (2019) describes the methods and baseline rates.
- How accurate are probability-of-success estimates?
- Accuracy depends on the model, the data and the phase. Vendor accuracy figures are self-reported, so ask how each model was validated and on which trials.
- Do I need a validation project to use AI for competitive intelligence?
- Usually not. Competitive intelligence uses public sources and no patient data, so it does not produce regulated deliverables. TrialMind's competitive intelligence work starts without a validation project.
See TrialMind on your own question
A 30-minute walkthrough on a study like yours, with sources and code you can check.
Sources · checked 2026-10-21
Product details come from each company’s public pages. Spotted something out of date? Tell us and we will correct it.
- Citeline Trialtrove+ product page
- Citeline Plus products and Ella
- Clarivate Cortellis Competitive Intelligence
- Clarivate: agentic AI across Cortellis (August 2026)
- GlobalData clinical trials data sources
- GlobalData Likelihood of Approval release (September 2025)
- Evaluate Pharma
- Evaluate Product Specific PTRS launch (2019)
- AlphaSense for pharma and biotech competitive intelligence
- Wong, Siah, Lo. Estimation of clinical trial success rates. Biostatistics 2019
- Fu et al. HINT: clinical-trial-outcome predictions. Patterns 2022
- Keiji AI: AACR 2026 abstract analysis
- TrialMind for Competitive & Portfolio Intelligence
- TrialPanorama (npj Digital Medicine, 2025)
- Lin et al. Panacea: a foundation model for clinical trial search, summarization, design, and recruitment. medRxiv 2024